Novel Therapeutics

A countermeasure for cystic fibrosis

Patients with cystic fribrosis have a unique condition with a reduced or absent function of a specific chloride-secreting protein.

  • Chloride secretion is essential for normal hydration and mucus production in lungs
  • Patients with cystic fibrosis have reduced or no function of CFTR (chloride channel)

Methods used by cystic fibrosis patients to improve airway clearance—such as bronchodialators, mucolytic agents, and antibiotics—don’t address insufficient chloride secretion. In preliminary studies with the Cystic Fibrosis Foundation, a new product by Entrinsic Health has been shown to substantially increase chloride secretion in cystic fibrosis patients, with a low risk of adverse interactions with other drugs. Entrinsic will continue developing this groundbreaking product to improve patient care.

View our product pipeline >